AmerisourceBergen buys Premier Source to expand biz

By Gareth Macdonald

- Last updated on GMT

Related tags: Sanofi-aventis

AmerisourceBergen has bought US consulting group Premier Source putting into practice the growth-through-acquisition strategy it outlined last month.

The deal will add Premier’s range of consulting services, which are designed to help drug firms, medical device makers and diagnostics developers with reimbursement issues, to AmerisourceBergen’s Consulting Services (ABCS) division.

In a press statement ABCS business development head Peyton Howell said: “Premier Source has been focused on the diagnostics market and their business complements the work we do in both our consulting businesses under the Lash Group and Xcenda​.”

AmerisourceBergen set out on the acquisition trail in early August when it announced it was looking to spend some of the $1.2bn (€1.4bn) cash reserve it had built up as a result of ‘strong’ second quarter sales.

The Pennsylvania-headquartered services firm said it was interested in buying specialty drug industry suppliers and, more pertinently given Premier’s line of business, consulting firms in the $200m to $300m price bracket.

CEO Steven Collis told investors that: “Our criteria for acquisitions are as follows: they should increase our value offering to existing customers, both up and down the channel; they should be within our established core competency; and they should increase shareholder value​.”

Broader business

AmerisourceBegen’s efforts to broaden its business also make strategic sense given that the firm expects revenues from several of its top selling products – including oxaliplatin, gemcitabine and docetaxel - to decline somewhat.

Foremost among these is oxaliplatin. AmerisourceBergen has sold the drug as a generic since 2010 after it bought a significant quantity while French drugmaker Sanofi, which holds rights to the branded version, struggled to fight off generic competition from other manufacturers.

‘Strong’ sales of oxaliplatin, as well as gemcitabine and docetaxel, helped boost AmerisourceBergen’s operating income 10 per cent in the quarter.

However, the firm’s oxaliplatin supplies have now run out which, coupled with Sanofi’s success in the courts​, means AmerisourceBergen will be unable to sell any more oxaliplatin until summer 2012.

Collis also expects docetaxel and gemcitabine sales to “moderate” as more suppliers enter the market and reimbursement declines.

Related news

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Related suppliers

Follow us


View more